New research: Trazodone could slow neurodegeneration

Many drugs placed on a target that show that they hit the targetA paper recently published in BRAIN suggests that a drug used to treat depression, known as Trazodone, could have a positive effect on neurodegenerative brain diseases, including Parkinson’s. The study led by Professor Giovanna Mallucci, at the Medical Research Council’s Toxicology Unit in Leicester and Cambridge University found Trazodone to be protective in their models of neurodegeneration.

 

Dr Richard Wyse, Director of Research and Development at The Cure Parkinson’s Trust commented:

“The Cure Parkinson’s Trust has been exploring Trazodone since July 2016 through its Linked Clinical Trials initiative, a programme that is specifically designed to move pre-approved drugs into clinical trial with urgency. The Linked Clinical Trials committee will continue to evaluate this compound with a view to fast-track it into clinical trials in people with Parkinson’s as soon as possible.”

Click here to read more about this research.

Click here to listen to Professor Mallucci talk to BBC Radio 4 TODAY (20/04/17) about this research.

 

 

RELATED ITEMS

  • At our patient advocate Rallying to the Challenge Meeting in 2014 it was unanimously agreed in the value of developing a clinical trials charter to significantly improve communication between those taking part in trials and those running clinical trials. The Charter was developed by people living with Parkinson's and clinicians…
  • Trials using treatments to slow, stop or reverse Parkinson’s The Cure Parkinson's Trust manage and facilitate an innovative research programme called Linked Clinical Trials with the sole aim of bringing forward treatments that biochemically show the potential to slow, stop or reverse Parkinson's. Each year around 25 compounds are evaluated…
  • Rallying to the challenge 2014 focused on how people with Parkinson’s (PwP) can strongly influence the effectiveness of clinical trials. Clinical trials are essential in assessing how effective or safe treatments are as well as advancing a greater understanding about a condition. The process of medicine development from test-tube to…
  • On the 17th October, the New Scientist reported exciting results from a six month study of twelve patients with Parkinson’s or Lewy Body Dementia taking an expensive cancer drug called nilotinib.  The article announced that scientists at Georgetown University Medical Centre in Washington had seen 'fast improvement' in the volunteers…
  • Dr David Devos is leading Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of Deferiprone, an iron-chelator in the treatment of people with Parkinson’s. 'The Cure Parkinson’s Trust…